I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 69% ± 23% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 69% ± 23% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 38% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 73478.02 | 226 / 226 | 97% | 3892.08 | 392 / 406 |
| kidney | 99% | 90.62 | 88 / 89 | 10% | 4.07 | 87 / 901 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.57 | 1 / 1 |
| spleen | 99% | 149.25 | 238 / 241 | 0% | 0 | 0 / 0 |
| lung | 95% | 24.98 | 547 / 578 | 4% | 0.34 | 46 / 1155 |
| breast | 84% | 14.99 | 387 / 459 | 14% | 0.70 | 154 / 1118 |
| uterus | 89% | 11.81 | 152 / 170 | 7% | 0.32 | 34 / 459 |
| esophagus | 94% | 17.75 | 1352 / 1445 | 3% | 0.05 | 5 / 183 |
| stomach | 90% | 13.19 | 323 / 359 | 5% | 0.07 | 13 / 286 |
| prostate | 90% | 13.89 | 221 / 245 | 4% | 0.17 | 21 / 502 |
| intestine | 90% | 15.53 | 871 / 966 | 4% | 4.74 | 19 / 527 |
| thymus | 90% | 18.38 | 590 / 653 | 2% | 0.06 | 13 / 605 |
| adrenal gland | 87% | 12.61 | 225 / 258 | 3% | 0.15 | 8 / 230 |
| pancreas | 76% | 10.26 | 250 / 328 | 14% | 0.61 | 25 / 178 |
| bladder | 81% | 13.67 | 17 / 21 | 8% | 0.40 | 39 / 504 |
| blood vessel | 88% | 13.82 | 1169 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 86% | 22.83 | 1031 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 86% | 90.00 | 795 / 929 | 0% | 0 | 0 / 0 |
| brain | 83% | 12.46 | 2200 / 2642 | 2% | 0.05 | 14 / 705 |
| skin | 77% | 11.94 | 1398 / 1809 | 6% | 0.32 | 29 / 472 |
| heart | 80% | 13.04 | 686 / 861 | 0% | 0 | 0 / 0 |
| muscle | 79% | 15.65 | 632 / 803 | 0% | 0 | 0 / 0 |
| ovary | 67% | 8.80 | 121 / 180 | 0% | 0.01 | 2 / 430 |
| lymph node | 0% | 0 | 0 / 0 | 7% | 0.09 | 2 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 2% | 0.03 | 1 / 45 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0030193 | Biological process | regulation of blood coagulation |
| GO_0007596 | Biological process | blood coagulation |
| GO_0005615 | Cellular component | extracellular space |
| GO_0072562 | Cellular component | blood microparticle |
| GO_0005788 | Cellular component | endoplasmic reticulum lumen |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005576 | Cellular component | extracellular region |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0002020 | Molecular function | protease binding |
| GO_0008201 | Molecular function | heparin binding |
| GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | SERPINC1 |
| Protein name | Antithrombin-III (Serpin C1) Antithrombin Antithrombin-III Antithrombin-III (ATIII) (Serpin C1) SERPINC1 protein SERPINC1 |
| Synonyms | PRO0309 AT3 |
| Description | FUNCTION: Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade . AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa . Its inhibitory activity is greatly enhanced in the presence of heparin. . |
| Accessions | A0A2U8KGL5 Q7KYY4 A0A0K0Q2Z1 A0A481U987 A0A481U728 Q8TCE1 A0A2H4R0R4 P01008 ENST00000367698.4 |
